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ABSTRACT
Objective: The aim of the study is to determine the prevalence of sleep-wake cycle disturbance in patient receiving chemotherapy.
Methods: A descriptive cross-sectional study was carried out in 2013. A total of 205 respondents, visiting Bhaktapur Cancer Hospital and who met 
eligible criteria were purposively sampled and interviewed face to face. Insomnia severity index (ISI) scale was used to grade insomnia. Descriptive 
statistics such as frequency and percentage was used to describe demographic data. Chi-square test was done to find out the association between 
prevalence of sleep-wake cycle disturbance and selected variables.
Results: Of 205 patients enrolled, 70.7% had sleep-wake cycle disturbances. The majority (71.21%) of respondents had some form of clinically 
significant insomnia. The ages of the patients ranged from 20 to 81 years with the mean age of 56.25 (standard deviation±13.87). More than half, 
i.e., 69.3% of the patients were female. Patients being treated with methotrexate were found to be more associated with the development of sleep-
wake cycle disturbance. Tea/coffee drinking habit was found to be significantly associated with the prevalence sleep-wake cycle disturbance.
Conclusion: Sleep disorders are a common and often chronic problem for patients with cancer. Until recently, such symptoms have attracted little 
attention. This might be one of the reasons for increased prevalence of sleep-wake cycle disturbance. The consequences of insomnia are often 
minimized relative to those of cancer itself. Insomnia is prevalent, under recognized, undermanaged, and understudied among patients with cancer 
receiving chemotherapy. It is recommended to take early and adequate intervention for the reduction of increased prevalence rate of sleep-wake cycle 
disturbance.
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INTRODUCTION
Sleep is an area of functioning that is frequently impaired in cancer 
patients. Sleep disorders, such as difficulty falling asleep, problems 
maintaining sleep, poor sleep efficiency, early awakening, and excessive 
daytime sleepiness, are prevalent in patients with cancer [1].
It is estimated that nearly 45% of oncology patients experience sleep 
disturbances; this is nearly three times the estimate of its occurrence in 
the general population [2].
The sleep of cancer patients is often disturbed, yet sleeps disorders and 
their health consequences are often neglected in this population [3,4]. 
Sleep disturbances affect between 30% and 75% of newly diagnosed 
or recently treated cancer patients, a rate that has been reported as 
double that of the general population [5]. Surveys have suggested that 
sleep complaints in cancer patients consisted of difficulty falling asleep 
and difficulty staying asleep, with frequent and prolonged nighttime 
awakenings. Patients reported these complaints both before treatment 
and during treatment [6,7].
Sleep dysfunction has unfortunately become an increasingly problematic 
issue for many and is a significant issue for many patients with cancer 
and their caregivers. Patient themselves may fail to report their sleep 
difficulties to their physicians. The consequences of insomnia are often 
minimized relative to those of cancer itself [8].
Sleep is an essential component of a healthy life. Disrupted sleep can 
lead to a variety of physical and psychological dysfunctions including 
insomnia, chronic pain, respiratory dysfunction, obesity, stress, and 
anxiety. Patients with cancer often are affected by side effects such 
as pain or depression that can manifest as insomnia. They also can 
experience sleep deprivation from side effects of the treatment such as 
anemia, daytime fatigue, and the physiologic effects of medications [8].
Sleep disturbance is one of the most frequent side effects experienced 
by patients with cancer. Several studies have shown that many patients 
with cancer do not mention their sleep problems, with close to 80% 
assuming it is caused by the treatment, 60% wrongly assuming that the 
symptoms will not last, and almost half believing that their physicians 
cannot do anything to help them.
Furthermore, these sleep disorders lead to pronounced symptom 
distress: Sarna gathered symptom distress data on female lung 
cancer patients an average of 1.8 years after treatment and found that 
insomnia was a major concern; it ranked as the third highest cause of 
distress after fatigue and pain [9]. Despite these concerns, insomnia is 
often undetected and undertreated when detected, with only 16.6% of 
patients in one study having spoken to their physician about their sleep 
problems [7,10]. Evidence suggests that patients may be hesitant to 
voluntarily report symptoms associated with cancer-related insomnia.
According to the journal of clinical oncology, the rate of insomnia 
in patients with cancer is found to be nearly three times higher than 
the rates in the general population. Insomnia is prevalent, under 
recognized, undermanaged, and understudied among patients with 
cancer receiving chemotherapy.
METHODS
A descriptive cross-sectional research design was used in In-patient and 
Out-patient Departments of Bhaktapur Cancer Hospital. It is one of the 
specialized cancer hospitals of Nepal. The study population consisted of 
all patients who have received at least one cycle of chemotherapy and 
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above 20 years of age attending this hospital and who were present at 
the time of data collection. A total of 205 respondents who met eligible 
criteria were purposively sampled and interviewed face to face.
A structured and semi-structured interview schedule consisting of 
questions-related demographic characteristics, type of cancer and 
insomnia severity index (ISI) for assessment of sleep-wake cycle 
disturbance developed by reviewing literature. The content validity of 
the instrument was established seeking the opinion of oncologist and 
related experts nurses and doctors. ISI is a standard scale whose validity 
and reliability is established. The instrument was then translated into 
the Nepali language, and opinion of language expert was obtained for 
comprehensibility and simplicity of language and for consistency of 
the content. The study was conducted after obtaining approval from 
the concerned authority. Anonymity, privacy, and confidentiality were 
maintained during as well as after data collection.
All patients who met the criteria and who gave informed consent were 
interviewed. Review of the patient’s medical record file was done 
to confirm the diagnosis and number of cycle of chemotherapy. The 
collected data were reviewed daily for completeness and accuracy. 
Edited data were entered into the Statistical Package for Social Science 
Software version 16.0 for statistical analysis using descriptive and 
inferential statistics.
RESULTS
Among total respondents, 50.7% of the total respondents fall under age 
60 and above, which is the largest age group. The ages of the patients 
ranged from 20 to 81 years with the mean age of 56.25 (standard 
deviation [SD]±13.87) at the time of the study. Regarding gender of the 
respondents, 69.3% were female and the remaining was male.
Among the total respondents, the majority (89.26%) of the patients 
in the study were non-smokers. Most (87.3%) of them were 
non-alcohol drinker, and majority (73.7%) of them were tea/coffee 
drinker (Table 1).
Out of total respondents, 25.4% had gynecological cancer, and minimal 
(2.4% each) had Non-Hodgkin’s lymphoma, thyroid cancer, and 
leukemia (Table 2).
Among the total respondents, <½ (43.41%) were administered 
oxali/cis/carboplatin and minimal (1.95% each) were administered 
cytarabine, gemcitabine, and others (Table 3).
Among the total respondents, 36.6% were receiving the second cycle of 
chemotherapy (Table 4).
The prevalence of sleep-wake cycle disturbance in the study was found 
to be 70.7% in Bhaktapur Cancer Hospital (Table 5).
In this study, more than half (54.63%) of the respondents had difficulty 
staying asleep (Table 6).
The majority (71.21%) of respondents had some form of clinically 
significant insomnia. The mean ISI score was 2.46 (±1.17) in the study 
(Table 7).
The prevalence of sleep-wake cycle disturbance in 65 years and 
above age group was more than in 65 years and below age group. The 
differences seen in these two age group was statistically significant 
(p=0.021) (Table 8).
The prevalence among the respondents drinking tea/coffee was 76.2%, 
whereas among non-drinker was 55.6%. The differences seen in these 
two group was statistically significant (p=0.004) (Table 9).
The prevalence among the respondents using methotrexate was 74.5%. 
The differences seen in these two group was statistically significant 
(p=0.01) (Table 10).
DISCUSSION
In this study, the ages of the patients involved ranged from 20 to 81 years 
with the mean age of 56.81 (SD±13.87) at the time of the study. The study 
group was categorized into six age groups. The majority (50.7%) of the 
patients were of age 60 years and above. More than half, i.e., 69.26% of 
the patients were female. This was quite similar to the study done in 
Canada, in which the ages ranged from 22 to 93 years, with mean age of 
58 years and the majority (72%) of the patients were female [11].
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Table 2: Description about disease-related information of 
respondents (n=205)
Cancer diagnosis Frequency (%)
Gynecological cancer 52 (25.4)
Breast cancer 35 (17.1)
Head and neck cancer 29 (14.1)
Stomach cancer 20 (9.8)
Lung cancer 19 (9.3)
Colorectal cancer 14 (6.8)
Bladder cancer 8 (3.9)
Others 7 (3.4)
Osteosarcoma 6 (2.9)
Non-Hodgkin’s lymphoma 5 (2.4)
Thyroid cancer 5 (2.4)
Leukemia 5 (2.4)
Table 3: Treatment-related information of respondents* 
(n=205)
















 Priyanka and Radha 
                                                                                                                                                                          Innovare Journal of Medical Science, Vol 4, Issue 3, 18-21
19
This study shows the prevalence of sleep-wake cycle disturbance 
to be 70.7% in Bhaktapur Cancer Hospital. This is consistent with 
the prospective study done, in 2010, in which the prevalence was 
87% [12]. Similarly, in the study done by Davidson et al., in 2002, found 
a prevalence of 32% in a diverse group of more than 1000 cancer 
patients, while the figure rose to 63% in a sample of 97 patients with 
breast cancer [13]. Similarly, in the descriptive retrospective study done 
by Boonstra, in 2010, among 69 patients found a prevalence of 74% as 
measured by the ISI [14]. In contrary, the findings of different studies 
have shown great variability in the prevalence rate of this disorder in 
cancer patients, ranging between 30% and 50%, though some studies 
have found much higher figures [15]. Other studies say the rate may 
be much higher 75% of all cancer patients reporting long and short 
term insomnia. Similarly, in the study done by Portenoy et al. found the 
prevalence rates of insomnia varying from 48.6% to 60% [16].
These discrepancies are considered to be due to the different 
methodologies used in the evaluation and the characteristics of the 
population studied or even due to the sample size used.
This study shows 71.21% of the participants have some degree of 
clinically significant insomnia. Similarly, in the descriptive retrospective 
study done by Boonstra et al. [14], among 69 found that 74% of patients 
had some form of clinically significant insomnia. This is consistent with 
the prospective study done in Florida, in which 75% of the participants 
had some degree of clinically significant insomnia [17].
This study shows that 46.82% of the patient had moderate to severe 
insomnia. This is consistent with the findings of the study done by 
Engstrom, in 1999, which showed that 50% of the patients rated their 
sleep problem as moderate, severe, or intolerable [7]. Similarly, in the 
study done by Degner, 1995 found the presence of moderate to severe 
insomnia among 30.9% of the patients [18]. In contrary is the findings 
of the study done by Harrison, in 1997, which showed that 41% of the 
patients had insomnia, out of which 78% reported moderate to severe 
insomnia [19].
This study shows that 49.26% had difficulty initiating sleep, 54.63% 
reported difficulty maintaining sleep, and 42.43% reported both 
initiating and maintaining sleep. This is consistent with the study 
conducted by Savard et al., in 2005, which found that 4% had difficulty 
initiating sleep, 34% reported difficulties maintaining sleep, and 52% 
reported both initiating and maintaining sleep issues [20]. Similarly, 
in the study done in Oncology Department, UK, found that 54% had 
conciliation insomnia, 18% complained of maintenance insomnia, and 
16% early morning awakening [21].
In this study, age is found to be an associated variable with sleep-wake 
cycle disturbance which is similar to the study done in Quebec, Canada 
(2008), in which there was a statistically significant association of 
overall insomnia complaints and prevalence of insomnia syndrome 
with age [22].
In this study, female had majority (71.8%) of insomnia prevalence 
which is consistent with some previous studies that have indicated that 
the female gender constitutes a significant risk factor for sleep-wake 
cycle disturbance [14]. Similarly, in a study done in New York found 
that male patients had a lower rate of insomnia complaints than female 
patients [22]. Furthermore, in the descriptive retrospective study 
done by Boonstra et al., found that 87% of women reported insomnia 
compared to 67% of men [14].
Table 4: Chemotherapy cycle-related information (n=205)






Table 5: Prevalence of sleep-wake cycle disturbance (n=205)
Sleep-wake cycle disturbances Frequency (%)
Absent 60 (29.3)
Present 145 (70.7)
Table 6: Insomnia problem-related information of the 
respondents (n=205)
Variables Frequency (%)
Difficulty falling asleep 101 (49.26)
Difficulty staying asleep 112 (54.63)
Problem waking up too early 87 (42.43)
Dissatisfied with current sleep pattern 87 (42.43)
Sleeping problems noticeable to others 68 (33.17)
Worried/distressed about current sleep problem 69 (33.65)
Sleep problem interference with daily functioning 86 (41.95)
Table 7: Grading of insomnia (n=205)
Grade of insomnia Frequency (%)
No clinically significant insomnia 59 (28.8)
Subthreshold insomnia 50 (24.4)
Moderate insomnia 39 (19.0)
Severe insomnia 57 (27.8)
(Mean ISI score is 2.46 and SD±1.17)
SD: Standard deviation
Table 8: Age and sleep-wake cycle disturbance of the 
respondents (n=205)
Age Sleep-wake cycle 
disturbance (%)





104 (75.9) 33 (24.1) 137 0.021
65 years 
and above
41 (60.3) 27 (39.7) 68 2.07
Total 145 60 205






Total p value Odd 
ratio
Present Absent
Drinker 115 (76.2) 36 (23.8) 151 0.004 2.55
Non-drinker 30 (55.6) 24 (44.4) 54
Total 145 60 205
Table 10: Use of methotrexate and sleep-wake cycle disturbance 
of the respondents (n=205)
Methotrexate Sleep-wake cycle 
disturbance (%)
Total p value Odd 
ratio
Present Absent
Yes 123 (74.5) 42 (25.5) 165 0.01 0.41
No 22 (55.0) 18 (45.0) 40
Total 145 60 205
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This study has clearly revealed the absence of an association between 
sleep-wake cycle disturbance and patients who had a history of 
smoking and/or are currently smoking and alcohol consumption. 
These findings are inconsistent with the findings in a prospective study 
done in Philadelphia [23]. These differences are considered to be due 
to different characteristics of the population studied or even due to the 
different sample size used.
This study has clearly revealed the presence of an association between 
sleep-wake cycle disturbance and patients who had a history of 
tea/coffee consumption and/or currently drinking tea/coffee. These 
findings are consistent with the findings in a prospective study done 
in Philadelphia (2004) that predicts caffeine use as patient-related risk 
factors [23]. Similarly, in the study done by Higdon and Frei in 2006, 
showed that as with other caffeinated beverages, such as coffee and 
colas, the caffeine contained in many tea products could potentially 
cause adverse effects including insomnia and restlessness [24].
Methotrexate is found to be significantly associated with sleep-wake 
cycle disturbance in this study. It is consistent with a study done by 
Kaya et al. (1983) where it is well documented that chemotherapy 
agents, such as antimetabolites, can lead to insomnia [25]. It is also 
consistent with a study done by National Cancer Institute which states 
that side effects of chemotherapy can be a source of sleep disturbances 
due to disrupted sleep cycles [13]. Similarly, in the study done by 
Catherine showed that antimetabolites cause the risk of developing 
sleep disturbance in about 10-29% of the patients [26].
In this study, the cycle of chemotherapy was not significantly associated 
with the prevalence of sleep-wake cycle disturbance. This is consistent 
with a study done in California (2012) that states that there were 
also no significant associations between insomnia and chemotherapy 
cycles [27].
Similarly, this is inconsistent with the findings in the study done by 
Savard et al. (2009), in which it was determined that initially sleep-wake 
patterns were disrupted, and progressively sleep-wake patterns 
worsened as the number of treatments received increased [28].
CONCLUSION
Focus should be given on reduction of the prevalence rate of sleep-wake 
cycle disturbance. This can be done by: Making the health personnel 
and patients conscious toward preventing sleep disturbances and 
promoting good sleep habit and setting up insomnia-counseling clinic 
in every cancer hospital to be launched by the trained nurses.
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